DEVELOPMENT OF A HUMANISED MOUSE MODEL FOR THE GENERATION OF MONOCLONAL ANTIBODIES. (Q4864588): Difference between revisions
Jump to navigation
Jump to search
(Created a new Item) |
(Changed label, description and/or aliases in pt) |
||||||
| (5 intermediate revisions by 2 users not shown) | |||||||
| label / pt | label / pt | ||||||
DESENVOLVIMENTO DE UM MODELO DE | DESENVOLVIMENTO DE UM MODELO DE MOUSE HUMANIZADO PARA A GERAÇÃO DE ANTIPOS MONOCLONAIS. | ||||||
| description / en | description / en | ||||||
Project Q4864588 in Italy | |||||||
| Property / summary: OVER THE YEARS MONOCLONAL ANTIBODIES (MABS) HAVE DEMONSTRATED THEIR EFFECTIVENESS FOR CLINICAL USE IN A WIDE RANGE OF CONDITIONS INCLUDING EBATTERY VIRAL INFECTIONS, AUTOIMMUNITY AND INFLAMMATION. (English) / qualifier | |||||||
readability score: 0.0119816246788188
| |||||||
| Property / summary | Property / summary | ||||||
Ao longo dos anos, os anticorpos monoclonais (MABS) demonstraram a sua eficácia para a utilização clínica numa vasta gama de condições, incluindo as infecções virais, a auto-imunidade e as inflamações. (Portuguese) | |||||||
| Property / contained in Local Administrative Unit | |||||||
| Property / contained in Local Administrative Unit: Roma / rank | |||||||
Normal rank | |||||||
| Property / Call for proposal | |||||||
| Property / Call for proposal: Avviso Progetti Strategici 2019 / rank | |||||||
Normal rank | |||||||
Latest revision as of 17:32, 12 October 2024
Project Q4864588 in Italy
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | DEVELOPMENT OF A HUMANISED MOUSE MODEL FOR THE GENERATION OF MONOCLONAL ANTIBODIES. |
Project Q4864588 in Italy |
Statements
233,753.62 Euro
0 references
469,035.91 Euro
0 references
49.84 percent
0 references
10 June 2020
0 references
ISTITUTI FISIOTERAPICI OSPITALIERI - IFO
0 references
TAKIS S.R.L.
0 references
ALLEVAMENTI PLAISANT SRL
0 references
OSPEDALE PEDIATRICO BAMBIN GESU IRCCS
0 references
NEL CORSO DEGLI ANNI GLI ANTICORPI MONOCLONALI (MABS) HANNO DIMOSTRATO LA LORO EFFICACIA PER L'USO CLINICO IN UNA VASTA GAMMA DI CONDIZIONI COMPRESE LE INFEZIONI VIRALI EBATTERICHE, AUTOIMMUNITÃ E INFIAMMAZION (Italian)
0 references
ПРЕЗ ГОДИНИТЕ МОНОКЛОНАЛНИТЕ АНТИТЕЛА (MABS) СА ПОКАЗАЛИ СВОЯТА ЕФЕКТИВНОСТ ЗА КЛИНИЧНА УПОТРЕБА ПРИ ШИРОК СПЕКТЪР ОТ СЪСТОЯНИЯ, ВКЛЮЧИТЕЛНО ВИРУСНИ ИНФЕКЦИИ НА EBATTERY, АВТОИМУННОСТ И ВЪЗПАЛЕНИЕ. (Bulgarian)
0 references
V PRŮBĚHU LET PROKÁZALY MONOKLONÁLNÍ PROTILÁTKY (MABS) SVOU ÚČINNOST PRO KLINICKÉ POUŽITÍ V ŠIROKÉ ŠKÁLE STAVŮ, VČETNĚ EBATTERY VIROVÝCH INFEKCÍ, AUTOIMUNITY A ZÁNĚTU. (Czech)
0 references
I ÅRENES LØB HAR MONOKLONALE ANTISTOFFER (MABS) VIST DERES EFFEKTIVITET TIL KLINISK BRUG UNDER EN LANG RÆKKE TILSTANDE, HERUNDER EBATTERY VIRUSINFEKTIONER, AUTOIMMUNITET OG INFLAMMATION. (Danish)
0 references
IM LAUFE DER JAHRE HABEN MONOKLONALE ANTIKÖRPER (MABS) IHRE WIRKSAMKEIT FÜR DIE KLINISCHE ANWENDUNG IN EINER VIELZAHL VON BEDINGUNGEN GEZEIGT, DARUNTER EBATTERY-VIRUSINFEKTIONEN, AUTOIMMUNITÄT UND ENTZÜNDUNGEN. (German)
0 references
ΜΕ ΤΗΝ ΠΆΡΟΔΟ ΤΩΝ ΕΤΏΝ, ΤΑ ΜΟΝΟΚΛΩΝΙΚΆ ΑΝΤΙΣΏΜΑΤΑ (MABS) ΈΧΟΥΝ ΑΠΟΔΕΊΞΕΙ ΤΗΝ ΑΠΟΤΕΛΕΣΜΑΤΙΚΌΤΗΤΆ ΤΟΥΣ ΓΙΑ ΚΛΙΝΙΚΉ ΧΡΉΣΗ ΣΕ ΈΝΑ ΕΥΡΎ ΦΆΣΜΑ ΠΑΘΉΣΕΩΝ, ΣΥΜΠΕΡΙΛΑΜΒΑΝΟΜΈΝΩΝ ΤΩΝ ΙΙΚΏΝ ΛΟΙΜΏΞΕΩΝ ΤΗΣ EBATTERY, ΤΗΣ ΑΥΤΟΑΝΟΣΊΑΣ ΚΑΙ ΤΗΣ ΦΛΕΓΜΟΝΉΣ. (Greek)
0 references
OVER THE YEARS MONOCLONAL ANTIBODIES (MABS) HAVE DEMONSTRATED THEIR EFFECTIVENESS FOR CLINICAL USE IN A WIDE RANGE OF CONDITIONS INCLUDING EBATTERY VIRAL INFECTIONS, AUTOIMMUNITY AND INFLAMMATION. (English)
0.0119816246788188
0 references
A LO LARGO DE LOS AÑOS, LOS ANTICUERPOS MONOCLONALES (MABS) HAN DEMOSTRADO SU EFECTIVIDAD PARA EL USO CLÍNICO EN UNA AMPLIA GAMA DE CONDICIONES, INCLUYENDO INFECCIONES VIRALES EBATTERY, AUTOINMUNIDAD E INFLAMACIÓN. (Spanish)
0 references
AASTATE JOOKSUL ON MONOKLONAALSED ANTIKEHAD (MABS) NÄIDANUD OMA EFEKTIIVSUST KLIINILISEL KASUTAMISEL PALJUDES TINGIMUSTES, SEALHULGAS EBATTERY VIIRUSINFEKTSIOONID, AUTOIMMUUNSUS JA PÕLETIK. (Estonian)
0 references
VUOSIEN MITTAAN MONOKLONAALISET VASTA-AINEET (MABS) OVAT OSOITTANEET TEHONSA KLIINISEEN KÄYTTÖÖN MONISSA ERI OLOSUHTEISSA, MUKAAN LUKIEN EBATTERY-VIRUSINFEKTIOT, AUTOIMMUNITEETTI JA TULEHDUS. (Finnish)
0 references
AU FIL DES ANS, LES ANTICORPS MONOCLONAUX (MABS) ONT DÉMONTRÉ LEUR EFFICACITÉ POUR UNE UTILISATION CLINIQUE DANS UN LARGE ÉVENTAIL DE CONDITIONS, Y COMPRIS LES INFECTIONS VIRALES EBATTERY, L’AUTO-IMMUNITÉ ET L’INFLAMMATION. (French)
0 references
LE BLIANTA ANUAS TÁ ANTASUBSTAINTÍ MONACLÓNACHA (MABS) TAR ÉIS A N-ÉIFEACHTACHT A LÉIRIÚ D’ÚSÁID CHLINICIÚIL I RAON LEATHAN COINNÍOLLACHA LENA N-ÁIRÍTEAR IONFHABHTUITHE VÍREASACHA CEALLRAÍ, UATHDHÍONACHAS AGUS ATHLASADH. (Irish)
0 references
TIJEKOM GODINA MONOKLONSKA PROTUTIJELA (MABS) POKAZALA SU SVOJU UČINKOVITOST ZA KLINIČKU PRIMJENU U ŠIROKOM RASPONU STANJA, UKLJUČUJUĆI VIRUSNE INFEKCIJE EBATTERY, AUTOIMUNITET I UPALU. (Croatian)
0 references
AZ ÉVEK SORÁN A MONOKLONÁLIS ANTITESTEK (MABS) KLINIKAILAG HATÁSOSNAK BIZONYULTAK SZÁMOS BETEGSÉGBEN, BELEÉRTVE AZ EBATTERY VÍRUSFERTŐZÉSEKET, AZ AUTOIMMUNITÁST ÉS A GYULLADÁST. (Hungarian)
0 references
PER DAUGELĮ METŲ MONOKLONINIAI ANTIKŪNAI (MABS) ĮRODĖ SAVO VEIKSMINGUMĄ KLINIKINIAM VARTOJIMUI ESANT ĮVAIRIOMS LIGOMS, ĮSKAITANT EBATTERY VIRUSINES INFEKCIJAS, AUTOIMUNIŠKUMĄ IR UŽDEGIMĄ. (Lithuanian)
0 references
GADU GAITĀ MONOKLONĀLĀS ANTIVIELAS (MABS) IR PIERĀDĪJUŠAS SAVU EFEKTIVITĀTI KLĪNISKAI LIETOŠANAI DAŽĀDOS STĀVOKĻOS, IESKAITOT EBATTERY VĪRUSU INFEKCIJAS, AUTOIMUNITĀTI UN IEKAISUMU. (Latvian)
0 references
MATUL IS-SNIN ANTIKORPI MONOKLONALI (MABS) UREW L-EFFIKAĊJA TAGĦHOM GĦALL-UŻU KLINIKU F’FIRXA WIESGĦA TA’ KUNDIZZJONIJIET LI JINKLUDU INFEZZJONIJIET VIRALI TAL-EBATTERY, AWTOIMMUNITÀ U INFJAMMAZZJONI. (Maltese)
0 references
IN DE LOOP DER JAREN HEBBEN MONOKLONALE ANTILICHAMEN (MABS) HUN EFFECTIVITEIT AANGETOOND VOOR KLINISCH GEBRUIK IN EEN BREED SCALA VAN AANDOENINGEN, WAARONDER EBATTERY VIRALE INFECTIES, AUTO-IMMUNITEIT EN ONTSTEKING. (Dutch)
0 references
Ao longo dos anos, os anticorpos monoclonais (MABS) demonstraram a sua eficácia para a utilização clínica numa vasta gama de condições, incluindo as infecções virais, a auto-imunidade e as inflamações. (Portuguese)
0 references
DE-A LUNGUL ANILOR, ANTICORPII MONOCLONALI (MABS) ȘI-AU DEMONSTRAT EFICACITATEA PENTRU UTILIZAREA CLINICĂ ÎNTR-O GAMĂ LARGĂ DE AFECȚIUNI, INCLUSIV INFECȚII VIRALE CU EBATTERY, AUTOIMUNITATE ȘI INFLAMAȚIE. (Romanian)
0 references
V PRIEBEHU ROKOV MONOKLONÁLNE PROTILÁTKY (MABS) PREUKÁZALI SVOJU ÚČINNOSŤ PRI KLINICKOM POUŽITÍ V ŠIROKEJ ŠKÁLE OCHORENÍ VRÁTANE EBATTERY VÍRUSOVÝCH INFEKCIÍ, AUTOIMUNITY A ZÁPALU. (Slovak)
0 references
V PRETEKLIH LETIH SO MONOKLONSKA PROTITELESA (MABS) POKAZALA SVOJO UČINKOVITOST PRI KLINIČNI UPORABI PRI NAJRAZLIČNEJŠIH STANJIH, VKLJUČNO Z VIRUSNIMI OKUŽBAMI EBATTERY, AVTOIMUNIČNOSTJO IN VNETJEM. (Slovenian)
0 references
UNDER ÅRENS LOPP HAR MONOKLONALA ANTIKROPPAR (MABS) VISAT SIN EFFEKTIVITET FÖR KLINISK ANVÄNDNING VID ETT BRETT SPEKTRUM AV TILLSTÅND, INKLUSIVE EBATTERY VIRUSINFEKTIONER, AUTOIMMUNITET OCH INFLAMMATION. (Swedish)
0 references
ROMA
0 references
10 April 2023
0 references